Literature DB >> 11085893

Somatic gene therapy for a neurodegenerative disease using microencapsulated recombinant cells.

C J Ross1, M Ralph, P L Chang.   

Abstract

Neurodegenerative diseases caused by lysosomal enzyme deficiencies are catastrophic illnesses with both peripheral organ and central nervous system abnormalities. The mucopolysaccharidosis type VII mouse with beta-glucuronidase deficiency was used to develop an alternate approach to gene therapy, in which a "universal" cell line engineered to secrete the missing enzyme is implanted directly into all recipients requiring the same enzyme replacement. The cells, though nonautologous, were rendered immunologically tolerable by protection in immunoisolating microcapsules. Since the blood-brain barrier impedes the passage of large molecules such as beta-glucuronidase, encapsulated cells producing beta-glucuronidase were introduced directly into the lateral ventricles of the brain. Based on this strategy, beta-glucuronidase was delivered throughout most of the central nervous system, reversing the histological pathology and reducing the previously elevated levels of lysosomal enzymes beta-hexosaminidase and alpha-galactosidase. The effectiveness of this approach was further demonstrated with improvements in the mutant circadian rhythm behavioral abnormalities. Compared to wild-type and heterozygous mice, the mutant mice had an unstable periodicity, fragmented activity, and a sixfold reduction in wheel running activity. After treatment, the mutant behavioral abnormalities were significantly improved with a more stable periodicity and a less fragmented pattern of activity. While the overall total activity level did not increase in the treated mutants, it did not show the deterioration observed in the sham-treated as well as in the untreated mutant mice. Hence, this alternative cell-based gene therapy demonstrates biochemical, histological, and behavioral efficacy and provides a potentially cost-effective and nonviral treatment applicable to all lysosomal storage diseases with neurological deficits. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11085893     DOI: 10.1006/exnr.2000.7531

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  8 in total

Review 1.  Factors influencing the use and interpretation of animal models in the development of parenteral drug delivery systems.

Authors:  Marilyn N Martinez
Journal:  AAPS J       Date:  2011-10-05       Impact factor: 4.009

Review 2.  Cell microencapsulation: a potential tool for the treatment of neuronopathic lysosomal storage diseases.

Authors:  Ursula Matte; Valeska Lizzi Lagranha; Talita Giacomet de Carvalho; Fabiana Quoos Mayer; Roberto Giugliani
Journal:  J Inherit Metab Dis       Date:  2011-05-26       Impact factor: 4.982

3.  In vitro correction of ARSA deficiency in human skin fibroblasts from metachromatic leukodystrophy patients after treatment with microencapsulated recombinant cells.

Authors:  Valeska Lizzi Lagranha; Guilherme Baldo; Talita Giacomet de Carvalho; Maira Burin; Maria Luiza Saraiva-Pereira; Ursula Matte; Roberto Giugliani
Journal:  Metab Brain Dis       Date:  2008-09-17       Impact factor: 3.584

4.  Intraventricular brain injection of adeno-associated virus type 1 (AAV1) in neonatal mice results in complementary patterns of neuronal transduction to AAV2 and total long-term correction of storage lesions in the brains of beta-glucuronidase-deficient mice.

Authors:  Marco A Passini; Deborah J Watson; Charles H Vite; Daniel J Landsburg; Alyson L Feigenbaum; John H Wolfe
Journal:  J Virol       Date:  2003-06       Impact factor: 5.103

5.  Estimation of the potential antitumor activity of microencapsulated Lactobacillus acidophilus yogurt formulation in the attenuation of tumorigenesis in Apc(Min/+) mice.

Authors:  Aleksandra Malgorzata Urbanska; Jasmine Bhathena; Christopher Martoni; Satya Prakash
Journal:  Dig Dis Sci       Date:  2008-07-17       Impact factor: 3.199

6.  Dysregulation of gene expression in a lysosomal storage disease varies between brain regions implicating unexpected mechanisms of neuropathology.

Authors:  Michael K Parente; Ramona Rozen; Cassia N Cearley; John H Wolfe
Journal:  PLoS One       Date:  2012-03-05       Impact factor: 3.240

7.  Colon-targeted delivery of live bacterial cell biotherapeutics including microencapsulated live bacterial cells.

Authors:  Satya Prakash; Aleksandra Malgorzata Urbanska
Journal:  Biologics       Date:  2008-09

8.  Bilateral single-site intracerebral injection of a nonpathogenic herpes simplex virus-1 vector decreases anxiogenic behavior in MPS VII mice.

Authors:  Wenpei Liu; Gerald Griffin; Trena Clarke; Michael K Parente; Rita J Valentino; John H Wolfe; Nigel W Fraser
Journal:  Mol Ther Methods Clin Dev       Date:  2015-01-28       Impact factor: 6.698

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.